Variable NVP group SVR/no. (%) LPV/r group SVR/no. (%) p univariate
Baseline HCV RNA level      
> 600000 IU/mL 18/31 (58) 21/68 (31) 0.01
< 600000 IU/mL 22/40 (55) 14/26 (53) 0.8
Liver fibrosis      
Advanced (F3-F4) 6/10 (60) 13/36 (36) 0.2
Non-advanced (F0-F2) 18/37 (47) 11/33 (33) 0.2
Cirrhosis      
Yes 3/3 (100) 8/22 (36) 0.07
No 21/44 (47) 16/47 (34) 0.2
Baseline LDL-cholesterol      
> 100 mg/dL 16/25 (64) 10/23 (43) 0.1
< 100 mg/dL 14/25 (56) 15/47 (32) 0.04
Baseline undetectable HIV viral load      
Yes 39/68 (57) 30/77 (39) 0.02
No 1/3 (33) 5/17 (29) 0.9
Time from starting NVP or LPV/r to beginning HCV therapy      
< 27 months 14/25 (56) 21/57 (36) 0.05
> 27 months 26/46 (56) 14/37 (37) 0.05
Time with undetectable HIV viral load before starting HCV therapy†*      
< 42 months 19/26 (73) 17/44 (39) 0.009
> 42 months 21/42 (50) 12/33 (37) 0.2
†Categorized by median.*Excluding patients with detectable HIV viral load at baseline. NVP: nevirapine. LPV/r: lopinavir/ritonavir.
Table 2: Sustained virologic response (SVR) in both treatment groups according to different variables.